Treatment of global and focal ischemia using naaladase inhibitor

Details Treatment of global and focal ischemia using naaladase inhibitor Treatment of global and focal ischemia using naaladase inhibitor

1997-07-08

1999-12-21

MacMillan, Keith D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

514 80, 514 89, 514 95, 514 99, 514574, 514921, A61K 3165

Patent

active

060049464

ABSTRACT:
The present invention includes compositions and methods of treatment for glutamate abnormalities and associated nervous tissue insult in a animal by inhibition of NAALADase enzyme. Compositions include glutamate-derived hydroxyphosphinyl derivative compounds, acidic peptide analogs, phosphinic acid derivatives and mixtures thereof that inhibit NAALADase enzyme activity and their use for treating glutamate abnormalities such as created by global and focal ischemia.

REFERENCES:
patent: H1312 (1994-05-01), Coughlin et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4741900 (1988-05-01), Alvarez et al.
patent: 4853326 (1989-08-01), Quash et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 4906779 (1990-03-01), Weber et al.
patent: 4918064 (1990-04-01), Cordi et al.
patent: 4937183 (1990-06-01), Ultee et al.
patent: 4950738 (1990-08-01), King et al.
patent: 4959493 (1990-09-01), Ohfume et al.
patent: 4966999 (1990-10-01), Coughlin et al.
patent: 4977155 (1990-12-01), Jacobsen et al.
patent: 4980356 (1990-12-01), Audiau et al.
patent: 4994446 (1991-02-01), Sokolovsky et al.
patent: 5011834 (1991-04-01), Weber et al.
patent: 5026717 (1991-06-01), Audiau et al.
patent: 5047227 (1991-09-01), Rodwell et al.
patent: 5057516 (1991-10-01), Jacobsen et al.
patent: 5068238 (1991-11-01), Jimonet
patent: 5075306 (1991-12-01), Jacobsen et al.
patent: 5079250 (1992-01-01), Jacobsen et al.
patent: 5093525 (1992-03-01), Weber et al.
patent: 5109001 (1992-04-01), Jacobsen et al.
patent: 5130330 (1992-07-01), Bowen et al.
patent: 5135080 (1992-08-01), Miller et al.
patent: 5140104 (1992-08-01), Coughlin et al.
patent: 5145862 (1992-09-01), Aizenman et al.
patent: 5156840 (1992-10-01), Goers et al.
patent: 5158976 (1992-10-01), Rosenberg
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5162512 (1992-11-01), King et al.
patent: 5177109 (1993-01-01), Cordi et al.
patent: 5190976 (1993-03-01), Weber et al.
patent: 5196439 (1993-03-01), Higurashi et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5236940 (1993-08-01), Phone-Poulenc Sante
patent: 5242915 (1993-09-01), Ueda et al.
patent: 5262568 (1993-11-01), Weber et al.
patent: 5283244 (1994-02-01), Yamnouchi
patent: 5284867 (1994-02-01), Benita et al.
patent: 5292765 (1994-03-01), Choi et al.
patent: 5326856 (1994-07-01), Coughlin et al.
patent: 5336689 (1994-08-01), Weber et al.
patent: 5340824 (1994-08-01), Gueremy et al.
patent: 5356902 (1994-10-01), Orstein
patent: 5403837 (1995-04-01), Audiau et al.
patent: 5403861 (1995-04-01), Fischer et al.
patent: 5434159 (1995-07-01), DeHaven-Hudkins et al.
patent: 5438130 (1995-08-01), McCormick et al.
patent: 5449761 (1995-09-01), Belinka, Jr. et al.
patent: 5459037 (1995-10-01), Erlander et al.
patent: 5473077 (1995-12-01), Monn et al.
patent: 5474547 (1995-12-01), Aebischer et al.
patent: 5478859 (1995-12-01), Drejer et al.
patent: 5486620 (1996-01-01), Monn
patent: 5489525 (1996-02-01), Pastan
patent: 5489717 (1996-02-01), Bigge et al.
patent: 5491241 (1996-02-01), Monn
patent: 5495042 (1996-02-01), Belinka, Jr. et al.
patent: 5500420 (1996-03-01), Maiese
patent: 5502166 (1996-03-01), Mishina
patent: 5521215 (1996-05-01), Benita et al.
patent: 5523307 (1996-06-01), Higurashi et al.
patent: 5527885 (1996-06-01), Coughlin et al.
patent: 5536721 (1996-07-01), Faarup et al.
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5594007 (1997-01-01), Chenard
Slusher et al., "Rat Brain N-Acetylated .alpha.-Linked Acidic Dipeptidase Activity," J. Bio. Chem., 1990, 265(34), 21297-21301.
Tsai et al., 61st Salmon Lecturer of the New York Academy of Medicine, Dec. 2-3, 1993, "Changes of Excitatory Neurotransmitter Metabolism in Schizophrenic Brains.".
Tsai et al., "Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS," Brain Research, 556, 1991, 151-156.
Rothstein et al., "Abnormal Excitatory Amino Acid Metabolism in Amyotrophic Lateral Sclerosis," Ann Neurol, 1990, 28, 18-25.
Tsai et al., "Immunocytochemical Distribution of N-acetylaspartylglutamate in the Rat Forebrain and Glutamatergic Pathways," J. Chem. Neuroanatomy, 1993, vol. 6, 277-292.
Subasinghe et al., Synthesis of Acyclic and Dehydroaspartic Acid Analogues of Ac-Asp-Glu-OH and Their Inhibition of Rat Brain N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALA Dipeptidase), J. Med. Chem 1990, 33, 2734-2744.
Slusher et al., Immunocytochemical Localization of the N-Acetyl-Aspartyl-Glutamate (NAAG) Hydrolyzing Enzyme N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase), J. Comparative Neurology, 1992, 315:217-229.
Stauch et al., "The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [.sup.3 H]NAAG catabolism in vivo," Neuroscience Letters, 1989, 100, 295-300.
Meyerhoff et al., "Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate," Brain Research, 593, 1992, 140-143.
Meyerhoff et al., "Activity of NAAG-hydrolyzing enzyme in brain may affect seizure susceptibility in genetically epilepsy-prone rats," Molecular Neurobiology of Epilepsy (Epilepsy Res. Suppl. 9), 1992, Chap. 16, 163-172.
Vornov, J., "Toxic NMDA-Receptor Activation Occurs During Recovery in a Tissue Culture Model of Ischemia," J. Neurochemistry, 1995, 65(4), 1681-1691.
Slusher et al., "NAALADase: A Potential Regulator of Synaptic Glutamate," DuPont NEN Notes, Spring 1994.
Jackson et al., "Design Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated .alpha.-Linked Acidic Dipeptidase," J. Medicinal Chem., 1995.
Carter et al., "Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase," Proc. Natl, Acad, Sci. USA, 1996, vol. 93, 749-753.
Coyle et al., "N-Acetyl-aspartyl Glutamate Recent Developments," Excitatory Amino Acids, 1991, 69-77.
Koenig et al., "N-acetyl-aspartyl-glutamate (NAAG) elicits rapid increase in intraneuronal Ca.sup.2+ in vitro," NeuroReport 5, 1063-1068, 1994.
Heston, W.D.W., "Potential Uses of Prostate Specific Membrane Antigen (PMSA): a Neurocarboxypeptidase and Membrane Folate Hydrolase," Urologe [A], v. 35, pp. 400-407 (1996).
Meyeroff, J. et al., "Genetically epilepsy prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate," Brain Research, 593 (1992).
Bhardwaj, A., "Striatal Nitric Oxide (NO) Production is Enhanced In Focal Cerebral Ischemia: An In Vivo Microdialysis Study," Society for Neuroscience 1996 Abstract Form, (1996).
Hurn, P., "Gender-Linked Injury After Focal Cerebral Ischemia," Scoiety for Nueroscience 1996 Abstract Form, (1996).
Tsai, G. et al., "Changes of excitatory neurotransmitter metabolism in schizophrenic brains," Salmon Lecturer of the New York Academy of Medicine, (Dec. 2-3, 1993).

Affiliated with

Also associated with

Rating

Treatment of global and focal ischemia using naaladase inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of global and focal ischemia using naaladase inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of global and focal ischemia using naaladase inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-505249